# AYTU BIOPHARMA, INC

AYTU BIOPHARMA, INC is an other.

## Overview

- **Organization type:** other
- **Assets under management:** Undisclosed
- **Website:** https://aytubiopharma.org

## Regulatory record

- **Reports private funds:** No

## About

AYTU Biopharma (formerly known as Aytu BioScience) was founded in 2015 as a specialty pharmaceutical company. The company's strategy centers on acquiring, developing, and commercializing late-stage or approved therapeutics, primarily in the women's health and urology segments. The firm also commercializes a portfolio of prescription and OTC products through its Aytu BioRx segment, which distributes compounded and branded medications. The company is headquartered in Englewood, Colorado, with additional operations in the United States. AYTU operates a hybrid model: it employs a small internal commercial team while outsourcing manufacturing to third-party contract manufacturers and conducting clinical trials through CROs. As of its most recent filings, AYTU reported total assets of $12.3 million and annual revenue of $8.5 million (per SEC filings, fiscal year 2024). The company is publicly traded on the Nasdaq under the ticker AYTU. AYTU's structural differentiator is its focus on drug repurposing and reformulation rather than novel drug discovery, reducing clinical risk. The company also maintains a high degree of operational leverage by relying on outsourced production and a virtual R&D model. However, the firm faces significant financial headwinds, including negative cash flow from operations and a diluted equity base.

## Sectors

- Biotech & Pharma
- Healthcare Services

## Questions

### What is AYTU Biopharma's primary therapeutic focus?

AYTU Biopharma focuses on women's health and urology, with lead asset AYF 31 for the treatment of vulvovaginal candidiasis. The company also distributes compounded and branded medications through its Aytu BioRx segment.

### How does AYTU Biopharma fund its operations?

AYTU funds operations through product sales revenue, equity and debt financings, and occasional strategic partnerships. As of fiscal year 2024, the company reported annual revenue of $8.5 million and total assets of $12.3 million (per SEC filings).

### What is AYTU's regulatory strategy?

AYTU pursues FDA approval through the 505(b)(2) regulatory pathway for its lead asset AYF 31, enabling reliance on existing safety data. The company has also explored an over-the-counter (OTC) switch for AYF 31 to expand market access.

## Related profiles

- [Four Seasons Education (Cayman) Inc.](https://altss.com/profile/four-seasons-education-cayman-inc)
- [Allarity Therapeutics](https://altss.com/profile/allarity-therapeutics-inc)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/aytu-biopharma-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology